What is the effect of Flomax (tamsulosin) on benign prostatic hyperplasia (BPH) in older males?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 17, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What Flomax (Tamsulosin) Does

Flomax (tamsulosin) is an alpha-1A and alpha-1D adrenergic receptor blocker that relaxes smooth muscle in the prostate and bladder neck, improving urinary flow and reducing bothersome lower urinary tract symptoms in men with benign prostatic hyperplasia. 1, 2

Mechanism of Action

Tamsulosin works by selectively blocking alpha-1A and alpha-1D receptors that predominate in the prostate gland, prostatic capsule, prostatic urethra, and bladder. 2 This receptor blockade causes relaxation of smooth muscle tissue in these areas, which reduces resistance to urine flow and alleviates both voiding symptoms (hesitancy, weak stream, incomplete emptying) and storage symptoms (frequency, urgency, nocturia). 3, 2

Clinical Effects and Efficacy

Symptom improvement: Tamsulosin 0.4 mg once daily reduces lower urinary tract symptom scores by approximately 25% in 65-80% of patients, with improvements typically beginning within 1 week of treatment. 4, 5 In controlled trials, the American Urological Association (AUA) symptom score decreased by 8.3-9.6 points from baseline (representing 12-16% improvement) compared to placebo. 1

Urinary flow enhancement: Peak urine flow rate (Qmax) increases by 1.1-3.6 mL/sec compared to baseline, with statistically significant improvements over placebo in clinical trials. 1, 6 This improvement reflects decreased urinary obstruction and enhanced bladder emptying. 2

Quality of life: Patients experience meaningful improvements in quality of life scores, with sustained benefits maintained for up to 6 years based on pooled long-term data. 2, 7

Important Clinical Limitations

Does not reduce prostate size: Tamsulosin does not affect prostate volume and therefore should not be used when the goal is to reduce prostate enlargement. 8 For men with significantly enlarged prostates requiring volume reduction, combination therapy with a 5-alpha-reductase inhibitor (finasteride or dutasteride) should be considered. 8

Does not prevent BPH progression: Long-term effectiveness in reducing complications from BPH progression (such as acute urinary retention or need for surgery) has not been established in available trials. 6

Dosing and Administration

The standard dose is 0.4 mg once daily in a modified-release formulation, taken after a meal. 8, 2 No initial dose titration is required, which distinguishes tamsulosin from older non-selective alpha blockers. 8, 4 The 0.8 mg dose provides only marginally greater benefit but substantially increases adverse effects. 1, 6

Adverse Effects Profile

Common side effects: The most frequent adverse events include dizziness, abnormal ejaculation (retrograde or delayed ejaculation in 4.5-14% of patients), asthenia, headache, and rhinitis. 2, 4 Ejaculatory dysfunction is more common with tamsulosin than with other alpha blockers. 8

Cardiovascular safety: Unlike older non-selective alpha blockers, tamsulosin at the 0.4 mg dose does not cause clinically significant changes in blood pressure, postural hypotension, or first-dose syncope, and does not interfere with concomitant antihypertensive therapy. 2, 4 This represents a major advantage over non-selective agents.

Surgical consideration: Tamsulosin is associated with intraoperative floppy iris syndrome during cataract surgery. 8 Patients planning ophthalmic procedures must inform their ophthalmologist about tamsulosin use, as this can complicate the surgical procedure. 8

Special Clinical Applications

Acute urinary retention: Tamsulosin facilitates successful voiding after catheter removal in men with benign prostatic hyperplasia and acute urinary retention, with standard dosing of 0.4 mg once daily. 8

Combination therapy: For men with both voiding and storage symptoms (overactive bladder), tamsulosin can be combined with antimuscarinics or mirabegron to address the full spectrum of lower urinary tract symptoms. 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Tamsulosin for the treatment of benign prostatic hypertrophy.

The Annals of pharmacotherapy, 2000

Research

OTC tamsulosin for benign prostatic hyperplasia.

Drug and therapeutics bulletin, 2010

Research

Tamsulosin for benign prostatic hyperplasia.

The Cochrane database of systematic reviews, 2003

Guideline

Tamsulosin Treatment for Benign Prostatic Hyperplasia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.